In this Issue:
Low testing rates for HBV-HDV co-infection in the US
Characterising HCV-neutralising anti-receptor Abs
Novel entecavir resistance mutations linked to viral breakthrough
Sofosbuvir + ribavirin treats HCV genotype 4
Long-term safety of oral nucleos(t)ide analogues in HBV infection
HCC risk in compensated cirrhosis with low HBV-DNA levels
Simeprevir + sofosbuvir in HCV with advanced cirrhosis
Ledipasvir + sofosbuvir in HIV-HCV co-infection
Daclatasvir + sofosbuvir in HIV-HCV co-infection
IFN-free regimens overcome effects of portal hypertension
Please login below to download this issue (PDF)